Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from Analysts at HC Wainwright

Stock analysts at HC Wainwright initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The firm set a “sell” rating and a $80.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential downside of 29.97% from the stock’s current price.

Several other research analysts also recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Needham & Company LLC restated a “buy” rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Guggenheim raised their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Robert W. Baird lowered their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $176.73.

Sarepta Therapeutics Trading Up 3.4 %

Shares of SRPT stock opened at $114.23 on Monday. Sarepta Therapeutics has a 1 year low of $78.67 and a 1 year high of $173.25. The stock has a 50 day simple moving average of $122.00 and a 200 day simple moving average of $131.52. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $10.91 billion, a P/E ratio of 91.38 and a beta of 0.81.

Insider Activity

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the company. Sunbelt Securities Inc. lifted its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after acquiring an additional 44,306 shares during the last quarter. M&T Bank Corp boosted its holdings in Sarepta Therapeutics by 8.5% during the 3rd quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company’s stock valued at $558,000 after acquiring an additional 349 shares during the period. Main Management ETF Advisors LLC purchased a new position in Sarepta Therapeutics during the 3rd quarter valued at $678,000. Finally, Kovitz Investment Group Partners LLC grew its position in Sarepta Therapeutics by 36.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 2,814 shares of the biotechnology company’s stock valued at $322,000 after acquiring an additional 755 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.